30 Day Trial

Anika Therapeutics Posts Orthobiologics Sales Growth for 2Q17/1H17


Anika Therapeutics posted 2Q17 orthobiologic revenue of US $24.5MM, +5.0% vs. 2Q16, and 1H17 revenue of $44.7MM, +4.2% vs. 1H16.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.